Clinical and translational biomarker-driven research
in malignant lymphoproliferative diseases
The iLymph research program aims at developing and validating biomarkers for: (1) early detection, disease progression, and recurrence of lymphoid malignancies; and, (2) risk assessment of patients with lymphoid malignancies (of B- or T-cell origin) in both the immunocompetent and immunodeficient clinical setting. As a support to these activities, iLymph projects also include development and improvement of specific technologies and methods for quantitative detection of novel biomarkers associated with lymphoid diseases.
Read more...